Catalog No.
EME51801
Expression system
Mammalian Cells
Species
Mus musculus (Mouse)
Protein length
Met1-Gln142
Predicted molecular weight
42.91 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q61606
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Glucagon receptor, GL-R, Gcgr
Differential Role of Phosphorylation in Glucagon Family Receptor Signaling Revealed by Mass Spectrometry., PMID:40503712
De novo design of miniprotein agonists and antagonists targeting G protein-coupled receptors., PMID:40501737
Chlorogenic acid and ferulic acid in SMYAD alleviate diabetic cardiomyopathy by inhibiting cardiac lipotoxicity via GCGR/PPARα and GCGR/AMPK pathways., PMID:40466507
Contractile effects of retatrutide in isolated mouse atrial preparations., PMID:40464942
Molecular Design of Unimolecular Tetra-Receptor Agonists., PMID:40461942
Decreased expression of insulin-degrading enzyme increases gluconeogenesis and glucose production in cultured hepatocytes administered with glucagon., PMID:40450129
Familial Mahvash disease with metastatic pancreatic NET and MEN1 mutations., PMID:40424057
GLP-1R/GCGR dual agonism dissipates hepatic steatosis to restore insulin sensitivity and rescue pancreatic β-cell function in obese male mice., PMID:40399267
The Glucagon Receptor Is Expressed in the Frontal Cortex and Impaired Signaling Associates With Cognitive Decline., PMID:40271226
GLP-1 and glucagon receptor dual agonism ameliorates kidney allograft fibrosis by improving lipid metabolism., PMID:40230860
A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans., PMID:40139439
Hepatic PKA Mediates Liver and Pancreatic α-Cell Cross Talk., PMID:40095004
Expression of glucocorticoid-receptor covaries with individual differences in visual lateralisation in zebrafish., PMID:40080219
Blockade of glucagon receptor induces α-cell hypersecretion by hyperaminoacidemia in mice., PMID:40075066
Constitutively active glucagon receptor drives high blood glucose in birds., PMID:40031956
Liver ALKBH5 regulates glucose and lipid homeostasis independently through GCGR and mTORC1 signaling., PMID:40014709
Female glucagon receptor knockout mice are prone to steatosis but resistant to weight gain when fed a MASH-promoting GAN diet and a high-fat diet., PMID:39985139
Regulation of GLP-1 and Glucagon Receptor Function by β-Arrestins in Metabolically Important Cell Types., PMID:39983043
MSA clustering enhances AF-Multimer's ability to predict conformational landscapes of protein-protein interactions., PMID:39735576
GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis., PMID:39735270
Hyperaminoacidemia from interrupted glucagon signaling increases pancreatic acinar cell proliferation and size via mTORC1 and YAP pathways., PMID:39720531
Effects of the combination of Epimedium brevicornum Maxim, Ligustrum lucidum Ait and Dexamethasone on asthmatic rats by endogenous glucocorticoid pathway., PMID:39694426
Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction., PMID:39663847
The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk., PMID:39609390
Characterization of LY3324954 a long-acting glucagon-receptor agonist., PMID:39603505
Interruption of glucagon signaling augments islet non-alpha cell proliferation in SLC7A2- and mTOR-dependent manners., PMID:39433176
Potential allosteric pockets identification of glucagon receptor based on molecular dynamics simulations., PMID:39393724
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors., PMID:39326429
Insights into the structure and activation mechanism of some class B1 GPCR family members., PMID:39240462
Isoquinoline small molecule ligands are agonists and probe-dependent allosteric modulators of the glucagon subfamily of GPCRs., PMID:39147328
The Inferential Binding Sites of GCGR for Small Molecules Using Protein Dynamic Conformations and Crystal Structures., PMID:39125959
Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration., PMID:39062586
Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity., PMID:38861859
Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity., PMID:38853300
CD9 Counteracts Liver Steatosis and Mediates GCGR Agonist Hepatic Effects., PMID:38837628
Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency., PMID:38755312
Intra-islet glucagon signalling regulates beta-cell connectivity, first-phase insulin secretion and glucose homoeostasis., PMID:38677509
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature., PMID:38612640
Glucagon does not directly stimulate pituitary secretion of ACTH, GH or copeptin., PMID:38604379
RNA expression changes driven by altered epigenetics status related to NASH etiology., PMID:38579398
The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection., PMID:38560764
The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies., PMID:38518602
Comparative analysis of paraspinal muscle imbalance between idiopathic scoliosis and congenital scoliosis from the transcriptome aspect., PMID:38440359
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity., PMID:38367045
Molecular features of the ligand-free GLP-1R, GCGR and GIPR in complex with Gs proteins., PMID:38346960
Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG1 antibody., PMID:38269489
Introduction of a fatty acid chain modification to prolong circulatory half-life of a radioligand towards glucose-dependent insulinotropic polypeptide receptor., PMID:38241936
Downregulation of the kidney glucagon receptor, essential for renal function and systemic homeostasis, contributes to chronic kidney disease., PMID:38237602
Adaptive infusion of a glucagon-like peptide-1/glucagon receptor co-agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial., PMID:38229453
G protein-coupled receptors and obesity., PMID:38161982
For research use only. Not for human or drug use.
